Chinook Therapeutics, Inc. (KDNY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chinook Therapeutics, Inc. (KDNY) trades at $40.39 with AI Score 53/100 (Grade B). Chinook Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for kidney diseases. Market cap: $2.71B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for KDNY: KDNY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KDNY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KDNY: the 7 perspectives are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Chinook Therapeutics, Inc. (KDNY) Healthcare & Pipeline Overview
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision medicines for kidney diseases, with a lead Phase III asset, atrasentan, targeting IgA nephropathy. The company's pipeline includes BION-1301 and CHK-336, positioning it as a key player in the renal therapeutics market, addressing rare and severe chronic kidney conditions.
What Is the Investment Thesis for KDNY?
Chinook Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focus on precision medicines for kidney diseases. The lead asset, atrasentan, in Phase III trials for IgA nephropathy, represents a significant near-term value driver. Positive trial results and subsequent regulatory approval could lead to substantial revenue generation, given the high unmet need in this patient population. The company's pipeline, including BION-1301 and CHK-336, offers additional upside potential. Chinook's gross margin of 71.9% indicates strong pricing power and efficient manufacturing processes. However, the company's negative profit margin of -3012.6% highlights the high R&D expenses associated with clinical-stage drug development. The company's beta of 0.67 suggests lower volatility compared to the overall market. Successful clinical trial outcomes, regulatory approvals, and strategic partnerships are key catalysts for future growth. Potential risks include clinical trial failures, regulatory setbacks, and competition from other companies developing kidney disease therapies.
Based on FMP financials and quantitative analysis
KDNY Key Highlights
- Atrasentan is in Phase III clinical trials for IgA nephropathy, a significant milestone indicating potential for near-term revenue generation.
- BION-1301 is in Phase I/II trial for IgA nephropathy, targeting the underlying cause of the disease.
- CHK-336 is an oral small molecule LDHA inhibitor in development for primary hyperoxaluria, addressing a rare genetic disorder.
- Gross margin of 71.9% demonstrates strong pricing power and efficient manufacturing processes.
- Market capitalization of $2.71B reflects investor confidence in the company's pipeline and potential.
Who Are KDNY's Competitors?
KDNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KDNY's Key Strengths?
- Strong pipeline of precision medicines for kidney diseases.
- Lead asset, atrasentan, in Phase III clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its technologies.
What Are KDNY's Weaknesses?
- High R&D expenses associated with clinical-stage drug development.
- Dependence on the success of its lead asset, atrasentan.
- Limited revenue generation until its therapies are approved and commercialized.
- Negative profit margin.
What Could Drive KDNY Stock Higher?
- Atrasentan Phase III trial data readout in IgA nephropathy expected in late 2026.
- BION-1301 Phase II trial data readout in IgA nephropathy expected in 2027.
- Enrollment and progress in ongoing clinical trials for atrasentan, BION-1301, and CHK-336.
- Potential for strategic partnerships or acquisitions to expand the company's pipeline and capabilities.
What Are the Key Risks for KDNY?
- Negative return on equity (-41.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or regulatory setbacks for atrasentan, BION-1301, or CHK-336.
- Competition from other companies developing kidney disease therapies.
- Changes in healthcare regulations or reimbursement policies.
- High R&D expenses associated with clinical-stage drug development.
- Dependence on the success of its lead asset, atrasentan.
What Are the Growth Opportunities for KDNY?
- Atrasentan Commercialization: Successful completion of Phase III trials and subsequent regulatory approval for atrasentan in IgA nephropathy represents a significant growth opportunity. The market for IgA nephropathy treatments is estimated to reach billions of dollars, and atrasentan could capture a substantial share with its efficacy and safety profile. Timeline: potential FDA approval within the next 1-2 years.
- BION-1301 Development: Advancing BION-1301 through clinical trials and demonstrating its efficacy in reducing APRIL levels could lead to a breakthrough therapy for IgA nephropathy. This would address the underlying cause of the disease and potentially prevent disease progression. The market for APRIL inhibitors is expected to grow rapidly. Timeline: Phase II data expected in 2027.
- CHK-336 for Primary Hyperoxaluria: Developing and commercializing CHK-336 for the treatment of primary hyperoxaluria represents a growth opportunity in a rare disease market. The limited treatment options for primary hyperoxaluria create a significant unmet need, and CHK-336 could become a valuable therapy for these patients. Timeline: Phase II/III trials planned for 2027.
- Expansion into Other Kidney Diseases: Leveraging its expertise in precision medicine, Chinook Therapeutics can expand its pipeline to include therapies for other rare and severe chronic kidney diseases. This would diversify its product portfolio and increase its revenue potential. The market for kidney disease treatments is vast and growing. Timeline: Ongoing research and development efforts.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with pharmaceutical companies or acquiring complementary technologies could accelerate the development and commercialization of Chinook's pipeline. This would provide access to additional resources, expertise, and market access. The biotechnology industry is characterized by frequent partnerships and acquisitions. Timeline: Ongoing business development activities.
What Opportunities Does KDNY Have?
- Successful completion of Phase III trials and regulatory approval for atrasentan.
- Expansion into other kidney diseases with its precision medicine approach.
- Strategic partnerships and acquisitions to accelerate development and commercialization.
- Growing market for kidney disease treatments.
What Threats Does KDNY Face?
- Clinical trial failures or regulatory setbacks.
- Competition from other companies developing kidney disease therapies.
- Changes in healthcare regulations or reimbursement policies.
- Intellectual property challenges.
What Are KDNY's Competitive Advantages?
- Proprietary pipeline of precision medicines for kidney diseases.
- Strong intellectual property protection for its technologies.
- Expertise in kidney disease biology and drug development.
- Established relationships with key opinion leaders in the field.
What Does KDNY Do?
Chinook Therapeutics, Inc., founded with the mission to transform the lives of individuals affected by kidney diseases, is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of precision medicines. The company's lead clinical program is atrasentan, an endothelin receptor antagonist currently in Phase III clinical trials for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Atrasentan aims to reduce proteinuria, a key driver of kidney disease progression. Chinook's pipeline also includes BION-1301, an anti-APRIL monoclonal antibody being evaluated in a Phase I/II trial for IgA nephropathy, targeting the underlying cause of the disease by reducing APRIL levels. Additionally, CHK-336, an oral small molecule LDHA inhibitor, is in development for the treatment of primary hyperoxaluria, a rare genetic disorder that leads to kidney stone formation and kidney damage. Chinook's research programs extend to other rare and severe chronic kidney diseases, leveraging precision medicine approaches to identify and develop targeted therapies. Headquartered in Seattle, Washington, Chinook Therapeutics operates with a team of 214 employees, focusing on innovation and clinical execution to bring novel treatments to patients with unmet needs in kidney disease.
What Products and Services Does KDNY Offer?
- Develops precision medicines for kidney diseases.
- Focuses on IgA nephropathy and other proteinuric glomerular diseases.
- Conducts Phase III clinical trials for atrasentan, an endothelin receptor antagonist.
- Evaluates BION-1301, an anti-APRIL monoclonal antibody, in Phase I/II trials.
- Develops CHK-336, an oral small molecule LDHA inhibitor, for primary hyperoxaluria.
- Conducts research programs for other rare and severe chronic kidney diseases.
How Does KDNY Make Money?
- Develops and commercializes precision medicines for kidney diseases.
- Generates revenue through the sale of its approved therapies.
- Partners with pharmaceutical companies for co-development and commercialization.
- Out-licenses its technologies to other companies.
What Industry Does KDNY Operate In?
The biotechnology industry is characterized by high growth potential, driven by innovation in drug development and increasing demand for novel therapies. The market for kidney disease treatments is substantial, with a growing prevalence of chronic kidney disease and limited treatment options. Chinook Therapeutics is positioned to capitalize on this trend with its focus on precision medicines for specific kidney diseases. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing kidney disease therapies. Chinook's precision medicine approach and pipeline of targeted therapies differentiate it from competitors.
Who Are KDNY's Key Customers?
- Patients with IgA nephropathy and other proteinuric glomerular diseases.
- Patients with primary hyperoxaluria.
- Healthcare providers who prescribe Chinook's therapies.
- Pharmaceutical companies that partner with Chinook.
Company Profile
Chinook Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Eric L. Dobmeier. KDNY has traded publicly since 2020.
Chinook Therapeutics, Inc. (KDNY) Valuation Context
Valued at $2.71B, KDNY is classified as a mid-cap stock. Relative to its peer group, KDNY's quantitative score of 53/100 is below the peer average of 87/100.
ROE -41%Key Financial Metrics
Return on equity for Chinook Therapeutics, Inc. stands at -41.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Chinook Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.69 places it in the safe zone, indicating low near-term bankruptcy risk.
KDNY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, a classic bullish signal.
- The community is buzzing about potential positive trial data, fueling optimism.
- Market perception seems to be shifting, with more analysts highlighting the company's pipeline.
- There's a growing belief that the company is undervalued compared to its peers, attracting attention.
Bear Case
- Some insiders have recently sold shares, raising concerns about their confidence.
- Community sentiment is wary due to past clinical trial setbacks, creating skepticism.
- The market is concerned about potential regulatory hurdles for their lead drug candidate.
- There are rumors of increased competition in the kidney disease space, potentially impacting future market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
KDNY Latest News
No recent news available for KDNY.
KDNY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KDNY.
Price Targets
Wall Street price target analysis for KDNY.
KDNY MoonshotScore
What does this score mean?
The MoonshotScore rates KDNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eric L. Dobmeier
CEO
Eric L. Dobmeier serves as the Chief Executive Officer of Chinook Therapeutics, bringing extensive experience in the biotechnology industry. Prior to joining Chinook, he held leadership positions at various pharmaceutical and biotechnology companies, including Seattle Genetics and Dendreon. His background encompasses strategic planning, business development, and commercialization of novel therapies. Dobmeier's expertise spans across multiple therapeutic areas, with a focus on oncology and immunology. He holds an MBA from Harvard Business School and a bachelor's degree in biology from the University of Washington.
Track Record: Under Eric L. Dobmeier's leadership, Chinook Therapeutics has advanced its pipeline of precision medicines for kidney diseases, with atrasentan progressing to Phase III clinical trials. He has overseen strategic partnerships and acquisitions to expand the company's capabilities and market reach. Dobmeier has also led successful fundraising efforts to support the company's research and development programs. His focus on innovation and clinical execution has positioned Chinook as a key player in the renal therapeutics market.
KDNY Healthcare Stock FAQ
What does Chinook Therapeutics, Inc. do?
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing precision medicines for kidney diseases. Their lead program, atrasentan, is in Phase III clinical trials for IgA nephropathy, a significant unmet need. The company also has BION-1301 in Phase I/II trials for IgA nephropathy and CHK-336 in development for primary hyperoxaluria. Chinook's business model revolves around advancing these therapies through clinical development, seeking regulatory approval, and ultimately commercializing them to improve the lives of patients with kidney diseases.
What do analysts say about KDNY stock?
Analyst consensus on KDNY stock reflects optimism regarding the company's pipeline and potential for growth in the kidney disease therapeutics market. Key valuation metrics include market capitalization, revenue projections (contingent on successful drug approvals), and potential earnings per share. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization of atrasentan and other pipeline assets. Analysts closely monitor clinical trial data, regulatory filings, and competitive landscape developments to assess KDNY's prospects. No buy/sell recommendations are provided here.
What are the main risks for KDNY?
The main risks for Chinook Therapeutics, Inc. include the inherent uncertainties of clinical-stage drug development, such as clinical trial failures or regulatory setbacks. Competition from other companies developing kidney disease therapies poses a threat to market share. Changes in healthcare regulations or reimbursement policies could impact the commercial viability of its therapies. The company's high R&D expenses and dependence on the success of its lead asset, atrasentan, also represent significant risks. Intellectual property challenges and potential product liability claims are additional considerations.
What are the key factors to evaluate for KDNY?
Chinook Therapeutics, Inc. (KDNY) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does KDNY data refresh on this page?
KDNY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KDNY's recent stock price performance?
Chinook Therapeutics, Inc. (KDNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline of precision medicines for kidney diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KDNY overvalued or undervalued right now?
Valuing Chinook Therapeutics, Inc. (KDNY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KDNY?
Before investing in Chinook Therapeutics, Inc. (KDNY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market conditions and competitive landscape may impact future performance.